ATLANTA, GA--(MARKET WIRE)--Jun 25, 2007 -- AtheroGenics, Inc. (NasdaqGM:AGIX - News), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced the extension of the maturity of a significant portion of the Company's convertible debt from 2008 to 2011. The restructuring of this debt obligation is part of AtheroGenics' updated business plan to advance the development of AGI-1067 in diabetes.
